NCT05684705

Study to Investigate the Penetration of Rifabutin Into the Lung After Multiple Intravenous Administrations of BV100

A Single Center, Open-label Study to Investigate the Penetration of Rifabutin Into the Lung After Multiple Intravenous Administrations of BV100 (rifabutin for Infusion) in Healthy Participants

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 35 (actual)
• Sponsor: BioVersys AG · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

Study to Investigate the Penetration of Rifabutin Into the Lung After Multiple Intravenous Administrations of BV100

Detailed description

This is a single center, open-label, monocentric, multiple IV dose, phase I study to investigate the penetration of rifabutin into the lung after multiple intravenous administrations of BV100 (rifabutin for infusion) in healthy participants.

Conditions

• Bacterial Infections

Interventions

Type	Name	Description
DRUG	BV100	Intravenous infusion

Timeline

• Start date: 2023-09-01
• Primary completion: 2024-10-30
• Completion: 2024-12-30
• First posted: 2023-01-13
• Last updated: 2025-01-14

Locations

1 site across 1 country: Austria